Communiqués Marvel Biosciences Corp.

Actions

MRVL

CA57384M1077

Recherche biotechnologique et médicale

Temps Différé Toronto S.E. 18:17:48 15/09/2026			Varia. 5j.	Varia. 1 janv.
0,1500 ^CAD	0,00%		+7,14%	+11,11%

05/08	Marvel Biosciences Corp. et Marvel Biotechnology Inc. annoncent des données précliniques positives : le MB-204 inverse les déficits comportementaux et cognitifs dans un modèle murin du syndrome de l'X fragile	CI
18/06	Marvel Biosciences Corp. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 avril 2026	CI

Communiqués

09/09	Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé	NE
09/09	Marvel Biosciences Announces Extension to Closing Date of Private Placement	NE
01/09	Marvel Biosciences Announces Grant of Deferred Share Units	NE
19/08	Marvel Biosciences Expands Private Placement to Quebec	NE
05/08	Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X	AQ
16/07	Marvel Biosciences Announces Private Placement for up to $3.0 Million	NE
26/06	New Autism Research to be Presented at European Purine Scientific Meeting	AQ
08/06	Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204	AQ
20/05	Marvel Biosciences Announces Grant of Deferred Share Units	NE
23/04	Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit	AQ
17/04	Marvel Biosciences Announces Closing of Convertible Debenture Offering	NE
16/04	Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders	AQ
13/04	Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering	NE
08/04	Marvel Biosciences Announces Proposed Convertible Debenture Offering	NE
30/03	Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204	GL
25/03	Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204	GL
25/03	Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204	AQ
18/03	Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204	NE
04/03	Marvel Biosciences Sponsors Scientific Meeting on Purines	NE
18/02	Marvel Biosciences Announces Grant of Deferred Share Units	NE
18/02	Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders	NE
03/02	Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204	NE
22/12	Bourse de Toronto, Marvel Biosciences Corp., Perspective de la haute direction	NE
22/12	Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite	NE
10/11	Marvel Biosciences Announces Grant of Deferred Share Units	NE